Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

PHASE3CompletedINTERVENTIONAL

Enrollment

425

Participants

Timeline

Start Date

September 4, 2021

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2023

Conditions

Alopecia Areata

Interventions

DRUG

Jaktinib

Administered orally.

DRUG

placebo

Administered orally.

Trial Locations (2)

Peking University People's Hospital, Beijing

Hospital for Skin Diseases, Chinese Academy of medical Sciences, Nanjing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT05051761 - Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata | Biotech Hunter | Biotech Hunter